Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044018 · ClinicalTrials.gov registry record · Phase 2
CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT00044018 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 102 participants.
The verdict
NCT00044018, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
The purpose of the study is to select the dose regimen of CDC-501 that provides the most promising evidence of efficacy.
Interventions
- DRUG CDC-501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2002-04-01 |
| Est. Completion | 2007-02-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00044018
The ClinicalTrials.gov registry entry for NCT00044018 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CDC-501 is the first listed.
NCT00044018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00044018 about?
NCT00044018 is a clinical study titled "CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma". The purpose of the study is to select the dose regimen of CDC-501 that provides the most promising evidence of efficacy.
What is the current status of trial NCT00044018?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2002-04-01. Estimated completion is 2007-02-15.
What interventions are being tested in trial NCT00044018?
The interventions under investigation include: CDC-501 (DRUG).
Who is sponsoring clinical trial NCT00044018?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.